Novel vectors and genes exhibiting increased expression
CA 2312291 A1 · Owner: The Immune Response Corporation · Inventors: Ill, Charles R.; Yang, Claire Q.; Gonzales, Jose E. N.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel genes and vectors exhibiting increased expression and novel splicing patterns are disclosed. The gene can comprise one or more consensus or near consensus splice sites which have been corrected. The gene can alternatively or additionally comprise one or more introns within coding or noncoding sequences. The gene can still further comprise modified 5' and/or 3' untranslated regions optimized to provide high levels and duration of tissuespecific expression. In one embodiment the gene comprises the coding region , of a full-length Factor VIII gene modified by adding an intron within the portion of the gene encoding the .beta.-domain so that the gene is expressed , as a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 25, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 25, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 25, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.